Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults - National Center for Health Statistics Rapid Surveys System, United States, October-November 2023.

IF 25.4 1区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

MMWR. Morbidity and mortality weekly report Pub Date : 2024-10-10 DOI:10.15585/mmwr.mm7340a1

Brooke S Staley, Lara R Robinson, Angelika H Claussen, Samuel M Katz, Melissa L Danielson, April D Summers, Sherry L Farr, Stephen J Blumberg, Sarah C Tinker

{"title":"Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults - National Center for Health Statistics Rapid Surveys System, United States, October-November 2023.","authors":"Brooke S Staley, Lara R Robinson, Angelika H Claussen, Samuel M Katz, Melissa L Danielson, April D Summers, Sherry L Farr, Stephen J Blumberg, Sarah C Tinker","doi":"10.15585/mmwr.mm7340a1","DOIUrl":null,"url":null,"abstract":"<p><p>Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that develops during childhood and can last into adulthood. Data from the National Center for Health Statistics Rapid Surveys System collected during October-November 2023 were used to estimate the prevalence of ADHD diagnosis and treatment among U.S. adults. In 2023, an estimated 15.5 million U.S. adults (6.0%) had a current ADHD diagnosis based on self-report; approximately one half received the diagnosis at age ≥18 years. Approximately one third of adults with ADHD took a stimulant medication to treat their ADHD in the previous year, 71.5% of whom had difficulty getting their ADHD prescription filled because it was unavailable. Approximately one half of adults with ADHD have ever used telehealth for ADHD-related services. Telehealth might have benefits for persons with ADHD, including helping them access behavioral treatment or medication prescriptions for ADHD. This report provides national estimates of the prevalence and treatment of ADHD among U.S. adults to help guide clinical care and regulatory decision-making for ADHD among U.S. adults.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 40","pages":"890-895"},"PeriodicalIF":25.4000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466376/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MMWR. Morbidity and mortality weekly report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.mm7340a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that develops during childhood and can last into adulthood. Data from the National Center for Health Statistics Rapid Surveys System collected during October-November 2023 were used to estimate the prevalence of ADHD diagnosis and treatment among U.S. adults. In 2023, an estimated 15.5 million U.S. adults (6.0%) had a current ADHD diagnosis based on self-report; approximately one half received the diagnosis at age ≥18 years. Approximately one third of adults with ADHD took a stimulant medication to treat their ADHD in the previous year, 71.5% of whom had difficulty getting their ADHD prescription filled because it was unavailable. Approximately one half of adults with ADHD have ever used telehealth for ADHD-related services. Telehealth might have benefits for persons with ADHD, including helping them access behavioral treatment or medication prescriptions for ADHD. This report provides national estimates of the prevalence and treatment of ADHD among U.S. adults to help guide clinical care and regulatory decision-making for ADHD among U.S. adults.

查看原文本刊更多论文

成人注意力缺陷/多动症诊断、治疗和远程保健使用情况 - 美国国家卫生统计中心快速调查系统，2023 年 10 月至 11 月。

注意力缺陷/多动障碍（ADHD）是一种神经发育障碍，在儿童时期发病，可持续到成年。美国国家卫生统计中心快速调查系统在 2023 年 10 月至 11 月期间收集的数据被用来估算美国成年人中多动症的诊断和治疗流行率。2023 年，根据自我报告，估计有 1550 万美国成年人（6.0%）目前被诊断患有多动症，其中约有一半是在年龄≥18 岁时被诊断出来的。在患有多动症的成年人中，约有三分之一的人在过去一年中服用了刺激性药物来治疗多动症，其中 71.5% 的人因无法获得多动症处方药而难以配药。约有一半的成人多动症患者曾经使用过远程保健来获得与多动症相关的服务。远程保健可能对多动症患者有益，包括帮助他们获得行为治疗或多动症药物处方。本报告提供了美国成年人多动症患病率和治疗情况的全国性估计数据，以帮助指导美国成年人多动症的临床治疗和监管决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

MMWR. Morbidity and mortality weekly report PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -

CiteScore

65.40

自引率

0.90%

发文量

309

期刊介绍： The Morbidity and Mortality Weekly Report (MMWR ) series is prepared by the Centers for Disease Control and Prevention (CDC). Often called “the voice of CDC,” the MMWR series is the agency’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. MMWR readership predominantly consists of physicians, nurses, public health practitioners, epidemiologists and other scientists, researchers, educators, and laboratorians.